10x Genomics, Inc. (TXG) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does 10x Genomics, Inc. Do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10x Genomics, Inc. (TXG) is classified as a mid-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO Serge Saxonov and employs approximately 1,240 people. With a market capitalization of $2.8B, TXG is one of the notable companies in the Technology sector.
10x Genomics, Inc. (TXG) Stock Rating — Hold (April 2026)
As of April 2026, 10x Genomics, Inc. receives a Hold rating with a composite score of 41.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TXG ranks #1,388 out of 4,446 stocks in our coverage universe. Within the Technology sector, 10x Genomics, Inc. ranks #153 of 584 stocks, placing it in the upper half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
TXG Stock Price and 52-Week Range
10x Genomics, Inc. (TXG) currently trades at $23.00. The 52-week high for TXG is $23.56, which means the stock is currently trading -2.4% from its annual peak. The 52-week low is $6.78, putting the stock 239.2% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.
Is TXG Overvalued or Undervalued? — Valuation Analysis
10x Genomics, Inc. (TXG) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.50x, versus the sector average of 3.16x. The price-to-sales ratio is 4.44x, compared to 1.06x for the average Technology stock.
At current multiples, 10x Genomics, Inc. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
10x Genomics, Inc. Profitability — ROE, Margins, and Quality Score
10x Genomics, Inc. (TXG) earns a quality factor score of 38/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7.9%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -6.0% versus the sector average of -1.0%.
On a margin basis, 10x Genomics, Inc. reports gross margins of 69.5%, compared to 50.9% for the sector. The operating margin is -14.2% (sector: -0.5%). Net profit margin stands at -11.1%, versus -1.5% for the average Technology stock. Revenue growth is running at -2.7% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
TXG Debt, Balance Sheet, and Financial Health
10x Genomics, Inc. has a debt-to-equity ratio of 31.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.46x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $433M.
TXG has a beta of 1.90, meaning it is more volatile than the broader market — a $10,000 investment in TXG would be expected to move 90.3% more than the S&P 500 on any given day. The stability factor score for 10x Genomics, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
10x Genomics, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, 10x Genomics, Inc. reported revenue of $628M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-63M. Gross margin was 69.5%. Operating income came in at $-83M.
In FY 2025, 10x Genomics, Inc. reported revenue of $643M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-44M. Gross margin was 69.0%. Revenue grew 5.2% year-over-year compared to FY 2024. Operating income came in at $-61M.
In Q3 2025, 10x Genomics, Inc. reported revenue of $149M and earnings per share (EPS) of $-0.22. Net income for the quarter was $-27M. Gross margin was 67.3%. Revenue grew -1.7% year-over-year compared to Q3 2024. Operating income came in at $-32M.
In Q2 2025, 10x Genomics, Inc. reported revenue of $173M and earnings per share (EPS) of $0.28. Net income for the quarter was $35M. Gross margin was 72.3%. Revenue grew 12.9% year-over-year compared to Q2 2024. Operating income came in at $30M.
Over the past 8 quarters, 10x Genomics, Inc. has demonstrated a growth trajectory, with revenue expanding from $153M to $628M. Investors analyzing TXG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
TXG Dividend Yield and Income Analysis
10x Genomics, Inc. (TXG) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.
TXG Momentum and Technical Analysis Profile
10x Genomics, Inc. (TXG) has a momentum factor score of 73/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
TXG vs Competitors — Technology Sector Ranking and Peer Comparison
Within the Technology sector, 10x Genomics, Inc. (TXG) ranks #153 out of 584 stocks based on the Blank Capital composite score. This places TXG in the upper half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.
Comparing TXG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TXG vs S&P 500 (SPY) comparison to assess how 10x Genomics, Inc. stacks up against the broader market across all factor dimensions.
TXG Next Earnings Date
No upcoming earnings date has been announced for 10x Genomics, Inc. (TXG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy TXG? — Investment Thesis Summary
10x Genomics, Inc. presents a balanced picture with arguments on both sides. The quality score of 38/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Price momentum is positive at 73/100, suggesting the trend favors buyers. High volatility (stability score 32/100) increases portfolio risk.
In summary, 10x Genomics, Inc. (TXG) earns a Hold rating with a composite score of 41.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TXG stock.
Related Resources for TXG Investors
Explore more research and tools: TXG vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TXG head-to-head with peers: TXG vs IHS, TXG vs VRSN, TXG vs ESE.